{"id":30511,"date":"-0001-11-30T00:00:00","date_gmt":"-0001-11-29T22:18:44","guid":{"rendered":""},"modified":"-0001-11-30T00:00:00","modified_gmt":"-0001-11-29T21:00:00","slug":"hepatitas","status":"publish","type":"catalog_entry","link":"https:\/\/www.pasveik.lt\/lt\/irasas\/hepatitas\/","title":{"rendered":"Hepatitas"},"content":{"rendered":"<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:center;line-height:normal\"\"=\"\"><strong>HEPATITAS<\/strong><\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:center;line-height:normal\"\"=\"\"><strong><\/strong><\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\"><strong>APIBR\u0116\u017dIMAS<\/strong><\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">Hepatitas &#8211;<br \/>\ntai bet kokios kilm\u0117s kepen\u0173 u\u017edegimas. Lig\u0105 gali sukelti:<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">-virusai<br \/>\nir bakterijos;<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">-toksini\u0173<br \/>\nmed\u017eiag\u0173 poveikis;<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">-kepen\u0173<br \/>\npa\u017eeidimas d\u0117l kraujotakos sutrikimo;<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">-autoimunin\u0117<br \/>\nliga;<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">-pilvo<br \/>\ntrauma kepen\u0173 srityje.<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\"><strong>EPIDEMIOLOGIJA<\/strong><\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">Da\u017eniausiai<br \/>\nhepatit\u0105 sukelia virusai: hepatito A virusas, hepatito B virusas ar hepatito C<br \/>\nvirusas. Kiti virusai, kurie gali sukelti kepen\u0173 u\u017edegim\u0105: hepatito D ir E<br \/>\nvirusai, citomegalo virusas (CMV), Epstein Barr virusas, v\u0117jaraupi\u0173 virusas.<br \/>\nHepatito B viruso infekcija yra viena svarbiausi\u0173 \u0161iuolaikin\u0117s medicinos<br \/>\nproblem\u0173. Pasaulyje apie 2 milijardus gyventoj\u0173 yra infekuoti HBV (hepatito B<br \/>\nviruso) infekcija. Kasmet mir\u0161ta apie 1 milijonas \u017emoni\u0173. Lietuvoje apie 2-7<br \/>\nprocentus gyventoj\u0173 yra HBV ne\u0161iotojai. Sergamumas hepatito C viruso (HCV)<br \/>\nsukelta infekcija pasaulyje svyruoja nuo 0.1 iki 5 proc. <\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\"><strong>LIGOS PRIE\u017dASTYS<br \/>\nIR EIGA<\/strong><\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">HBV<br \/>\npriklauso Hepadnaviridae \u0161eimai, tai yra DNR virusas. U\u017esikre\u010diama: <\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">\u2022Heteroseksuali\u0173<br \/>\nsantyki\u0173 metu su sergan\u010diu partneriu (41 proc.);<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">\u2022Vartojant<br \/>\nintraveninius narkotikus, kai adata dalinamasi su sergan\u010diuoju (15 proc.);\u2022<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">\u2022Homoseksuali\u0173<br \/>\nsantyki\u0173 su sergan\u010diuoju metu (9 proc.);<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">\u2022Buitinio<br \/>\nkontakto su sergan\u010diuoju metu (2 proc.);<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">\u2022Profesinio<br \/>\nmedicinos darbuotoj\u0173 kontakto metu (1 proc.);<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">\u2022Ne\u017einomas<br \/>\nu\u017esikr\u0117timo kelias (1 proc.).<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">Virusas<br \/>\npatek\u0119s \u012f organizm\u0105 puola kepen\u0173 l\u0105steles ir jas infekuoja. Tuomet suaktyvinama<br \/>\norganizmo sistema- imuninis atsakas nukreiptas prie\u0161 infekuotas kepen\u0173<br \/>\nl\u0105steles. Jei imunin\u0117s sistemos aktyvumas pakankamas, virusas eliminuojamas i\u0161<br \/>\norganizmo. Kitu atveju, infekcija sukelia l\u0117tin\u012f hepatit\u0105. L\u0117tinio hepatito<br \/>\npasekm\u0117s yra kepen\u0173 ciroz\u0117 (rand\u0117jimas), kepen\u0173 v\u0117\u017eys ir kepen\u0173 funkcijos<br \/>\nnepakankamumas.<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">HCV<br \/>\nvirusas yra RNR virusas. HCV u\u017esikr\u0117timo keliai:<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">\u2022Per<br \/>\n\u0161virk\u0161tus;<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">\u2022Kraujo<br \/>\nperpylimai(iki 1992 met\u0173);<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">\u2022Hemodializ\u0117s<br \/>\nmetu;<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">\u2022Per<br \/>\nseksualinius kontaktus;<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">\u2022Infekuota<br \/>\nmotina gali perduoti vaisiui.<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">HCV<br \/>\nvirusas tiesiogiai \u017ealoja hepatocitus. 15-30 proc. u\u017esikr\u0117tusi\u0173\u016bmia HCV<br \/>\ninfekcija pasveiksta, o likusiems asmenims infekcija pereina \u012f l\u0117tin\u0119 form\u0105.<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\"><strong>KLINIKA<\/strong><\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\">Po u\u017esikr\u0117timo<br \/>\nHBV, pra\u0117jus 1savaitei -1 m\u0117nesiui, pasirei\u0161kia simptomai, kurie yra<br \/>\nnespecifiniai:<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\">\u2022Silpnumas, <\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\">\u2022Apetito stoka,<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\">\u2022\u0160leik\u0161tulys,<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\">\u2022Kar\u0161\u010diavimas,<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\">\u2022S\u0105nari\u0173 skausmas,<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\">\u2022Odos nie\u017eulys,<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\">\u2022Skausmas<br \/>\nde\u0161in\u0117je pa\u0161on\u0117je,<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\">\u2022Odos b\u0117rimas,<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\">\u2022Patams\u0117ja<br \/>\n\u0161lapimas, pa\u0161vies\u0117ja i\u0161matos.<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\">2-3 savait\u0119 po<br \/>\nu\u017esikr\u0117timo pradeda ry\u0161k\u0117ti odos ir gleivini\u0173 pageltimas, nes kepenys nebegali<br \/>\ni\u0161 kraujo pa\u0161alinti pigmento bilirubino ir padid\u0117j\u0119s jo kiekis suteikia spalv\u0105<br \/>\nodai ir gleivin\u0117ms.<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\">Tre\u010ddaliui<br \/>\nu\u017esikr\u0117tusi\u0173 HBV infekcija nepasirei\u0161kia jokiais simptomais.<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\">Vienam i\u0161 penki\u0173<br \/>\nligoni\u0173 infekcija pereina \u012f l\u0117tin\u0119 form\u0105- asmuo atrodo sveikas, ta\u010diau jis yra<br \/>\nvirus\u0173 ne\u0161iotojas arba pasirei\u0161kia l\u0117tinis aktyvus hepatitas, kuomet simptomai<br \/>\npana\u0161\u016bs \u012f \u016bmios faz\u0117s klinikin\u012f pasirei\u0161kim\u0105.<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\">L\u0117tinis HCV<br \/>\nhepatitas da\u017enai nepasirei\u0161kia jokiais simptomais, daliai ligoni\u0173 gali b\u016bti<br \/>\njau\u010diamas silpnumas, pykinimas, nie\u017eulys ir diskomforto jausmas po \u0161onkauliais de\u0161in\u0117je<br \/>\npus\u0117je. HCV infekcija gali pa\u017eeisti ir kitas organizmo sistemas- pasirei\u0161kia<br \/>\nkrioglobulinemija (kraujyje yra pakit\u0119 baltymai, kurie agliutinuoja \u017eemoje<br \/>\ntemperat\u016broje), odos pa\u017eeidimais, s\u0105nari\u0173 ir raumen\u0173 skausmais, inkst\u0173 ligomis,<br \/>\nnerv\u0173 ar endokrinin\u0117s sistemos pa\u017eeidimais.<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\"><strong>DIAGNOSTIKA<\/strong><\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\">Hepatitas B yra<br \/>\n\u012ftarimas, kai apklausiant ligon\u012f ar fizin\u0117s jo ap\u017ei\u016bros metu i\u0161ai\u0161k\u0117ja rizikos<br \/>\nfaktoriai ar simptomai b\u016bdingi HBV infekcijai. Tuomet atliekami specifi\u0161ki<br \/>\nkraujo tyrimai, padedantys nustatyti HBV. Kraujyje ie\u0161koma HBV antigen\u0173 ir<br \/>\nantik\u016bni\u0173 prie\u0161 juos. Tyrimai taip pat padeda nustatyti infekcijos \u016bmum\u0105. HBV<br \/>\nturi tris antigenus, kurie da\u017eniausiai naudojami atliekant HBV testus \u2013<br \/>\npavir\u0161iaus antigenas HbsAg, \u0161erdinis antigenas HbcAg ir E antigenas HbeAg. Taip<br \/>\npat atliekama kepen\u0173 biopsija ir histologinis tyrimas, vertinamas kepen\u0173<br \/>\nferment\u0173 kiekis kraujyje \u2013 i\u0161siai\u0161kinamas kepen\u0173 strukt\u016bros ir funkcijos<br \/>\npa\u017eeidimo laipsnis.<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\">HCV infekcija<br \/>\ntaip pat \u012ftariama remiantis rizikos veiksniais (intraveninis narkomanas,<br \/>\nperpiltas kraujas iki 1992 met\u0173 ir t.t.). Kadangi klini\u0161kai infekcija<br \/>\nda\u017eniausiai nepasirei\u0161kia, neretai HCV infekcija randama atsitiktinai atliekant<br \/>\ntyrimus. Diagnozuojant HCV tiriami kepen\u0173 fermentai (AST, ALT) kraujyje- j\u0173<br \/>\nkiekis b\u016bna padid\u0117j\u0119s; atliekami virusologiniai tyrimai (antiHCV, HCV RNR<br \/>\nnustatymas kraujyje, viruso genotipo identifikavimas<a><\/a>).<br \/>\nTaip pat atliekama kepen\u0173 biopsija ir histologinis tyrimas. <\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\"><strong>GYDYMAS<\/strong><\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\">Did\u017eiajai daliai<br \/>\nu\u017esikr\u0117tusi\u0173 tiek HBV, tiek HCV infekcija pakanka poilsio re\u017eimo, tinkamos<br \/>\nmitybos ir jie visi\u0161kai pasveiksta. Vis d\u0117lto, jie turi b\u016bti stebimi, kad<br \/>\nnei\u0161sivystyt\u0173 l\u0117tin\u0117s ligos ir tokiems asmenims turi b\u016bti paai\u0161kinama, kaip jie<br \/>\nturi elgtis, kad neplatint\u0173 viruso.<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\">Jei HBV ar HCV infekcija<br \/>\ntrunka ilgiau kaip 6 m\u0117nesius (l\u0117tin\u0117 virusin\u0117 infekcija, kuomet virusai<br \/>\norganizme nuolat dauginasi) taikomas medikamentinis gydymas. HBV infekcija<br \/>\ngydoma alfa interferonu arba lamivudinu arba \u0161i\u0173 vaist\u0173 deriniu. Alfa<br \/>\ninterferonas yra injekcijomis \u012f paod\u012f leid\u017eiamas biologinismedikamentas, kuris<br \/>\nskatina imunin\u0119 sitem\u0105 kovoti su virusais. Lamivudinas- taiantivirusiniai<br \/>\nvaistai, vadinami nukleozid\u0173 analogais, kurie slopina pat\u012f virus\u0105.&nbsp; L\u0117tinio HCV hepatito gydymas yra kombinuotas-<br \/>\nskiriamas interferonas ir nukleozid\u0173 anlogas (ramivudinas). L\u0117tiniam hepatitui<br \/>\ngydyti naudojami medikamentai turi stipr\u0173 poveik\u012f organizmui, tod\u0117l da\u017enos<br \/>\nnepageidaujamos reakcijos.<\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"=\"\"><strong>PROFILAKTIKA<\/strong><\/p>\n<p style=\"text-align: justify;\" margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal\"\"=\"\">Geriausia<br \/>\nHBV profilaktikos priemon\u0117 yra skiepai. B\u016btinai pasiskiepyti tur\u0117t\u0173 asmenys,<br \/>\ngyvenantys su asmeniu, turin\u010diu \u0161\u012f virus\u0105. Taip pat b\u016btinai paskiepyti reikia<br \/>\nnaujagimius, vaikus. Pasiskiepyti tur\u0117t\u0173 ir padidintos rizikos asmenys<br \/>\n(medicininis personalas, kal\u0117jim\u0173 darbuotojai ir pan.), asmenys, kuriems<br \/>\natliekamos hemodializ\u0117s. Skiepijama tris kartus: antra vakcinos doz\u0117 skiriama<br \/>\npra\u0117jus m\u0117nesiui po pirmosios, tre\u010dia &#8211; pra\u0117jus 6 m\u0117nesiams. Paprastai daugelis<br \/>\npo vakcinacijos \u012fgyja ilgalaik\u012f imunitet\u0105. Apie skiep\u0173 efektyvum\u0105 sprend\u017eiama<br \/>\npagal apsaugini\u0173 antik\u016bn\u0173 titr\u0105 (anti-Hbs). Skiepai nepad\u0117s jau sergantiems.<br \/>\nTaip pat \u0161ie skiepai neapsaugos nuo hepatito A, hepatito C ar kit\u0173 kepen\u0173 lig\u0173.<br \/>\nNuo HCV skiep\u0173 kol kas n\u0117ra sukurta, tod\u0117l vienintel\u0117 apsaugos priemon\u0117- profilaktikos<br \/>\npriemon\u0117s, kurios stabdo viruso plitim\u0105. <\/p>\n<div style=\"text-align:justify\"><\/div>\n","protected":false},"featured_media":30512,"template":"","tags":[1632,28039,28040,28038],"catalog_supplier":[],"catalog":[27448],"class_list":["post-30511","catalog_entry","type-catalog_entry","status-publish","has-post-thumbnail","hentry","tag-hepatitas","tag-hepatitas-a","tag-hepatitas-b","tag-kepenu-uzdegimas","catalog-virskinimo-organu-ligos"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/catalog_entry\/30511","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/catalog_entry"}],"about":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/types\/catalog_entry"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/media\/30512"}],"wp:attachment":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/media?parent=30511"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/tags?post=30511"},{"taxonomy":"catalog_supplier","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/catalog_supplier?post=30511"},{"taxonomy":"catalog","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/catalog?post=30511"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}